An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.
about
A new insight into hepatitis C vaccine developmentChikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoffA novel self-replicating chimeric lentivirus-like particleIncreased Immunogenicity of a DNA-Launched Venezuelan Equine Encephalitis Virus-Based Replicon DNA VaccineInduction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2Identification and characterization of interferon-induced proteins that inhibit alphavirus replicationComparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in miceRapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats.Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design.A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measlesCharacterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvantHighly efficient, chemically defined and fully scalable biphasic production of vaccine viruses.Glycoprotein is enough for sindbis virus-derived DNA vector to express heterogenous genes.Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.A cationic nanoemulsion for the delivery of next-generation RNA vaccines.Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in SituA call for replicating vector prime-protein boost strategies in HIV vaccine design.Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunitySelf-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral ChallengeNonviral delivery of self-amplifying RNA vaccines.Prospects for a vaccine against the hepatitis C virus.Cellular factors influencing Semliki Forest Virus vector biology.Replicating and non-replicating viral vectors for vaccine developmentUse of viral vectors for the development of vaccines.Cytoplasmic RNA viruses as potential vehicles for the delivery of therapeutic small RNAs.Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis.Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single doseSystemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.Therapeutic and prophylactic applications of alphavirus vectors.Similarities and differences in antagonism of neuron alpha/beta interferon responses by Venezuelan equine encephalitis and Sindbis alphaviruses.Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future PerspectivesNucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.Self-replicating alphavirus RNA vaccines.Host translation shutoff mediated by non-structural protein 2 is a critical factor in the antiviral state resistance of Venezuelan equine encephalitis virus.CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.
P2860
Q21296858-82495E46-F6A6-40B2-A242-4A82568BAE51Q24606603-4C746FFF-CEF1-4101-AF41-375F95819661Q24611993-510B369D-7CF8-449D-8698-4D3EA85CBFB4Q27485003-41B293BE-2687-4653-B024-79513E59BC54Q27486582-F7A0A1BE-C94C-4D07-ADDA-7D5E207A861AQ28506953-457110AC-7F01-4602-8AA8-7A0CD537D8D2Q28752489-9B0E6A19-3417-4329-B716-AC39FF6B400DQ30375250-DD511A06-D4FD-4A7E-82A6-29261025A0C7Q33351971-CFD893F3-B4B3-4529-B049-58CC06F434E6Q33646948-0BDAA7FA-5B74-49D5-92C4-8209A530D1F6Q33769306-3DD97F12-5A47-4C75-A07A-4FEEA8885F30Q33788861-82C62EE9-E726-4EBA-83DC-ACCE96221787Q33877513-441CBBFB-41C9-41FB-A743-CD2790BA5C11Q34175601-46AAAC87-1E0B-4A64-919D-4B93FB60283CQ35142308-452A1A6B-1069-43AD-9C6B-CDBEAC5D654DQ35558828-4FD4313B-295E-4392-95C4-A4EED5C7B3D8Q35600305-5AA26795-BB8E-4B32-81F4-95E057F15200Q35826688-54494100-06F7-4BAF-B64A-F8399B535DF4Q35851801-7D35EECD-DE06-41B2-B592-1CDC7C4DA7D5Q35946943-140348D3-7BF2-43BE-9A31-385DDAFE503BQ35953762-9473C931-CDD9-410D-A8CF-AAF827BFA09BQ36086236-5D293444-EAEF-491E-BEC7-2764051C310BQ36104042-52676780-8AF4-49BE-8B21-11420D29DCE6Q36221799-B6166591-1237-4100-B866-9E0E278D773DQ36233831-69D40EFE-A3C5-41DA-9F1E-A2B829C90B99Q36288885-32309395-171A-4400-8DAB-4C1D056ED809Q36464587-FE5179DB-87E1-421E-8BE1-275D6502706AQ36780156-AC778666-089F-4BE5-A063-D05A98D569ACQ36937406-173DAB20-1DB8-4132-B553-6721ADF75CFDQ36949568-33CB00CA-57AD-4E33-9190-DAB3EEF35C2AQ37033291-5D32A10E-2774-49DF-AAAF-20649EC929AAQ37126611-FFFE0D4D-2EDB-4B53-BC91-44E754C212F3Q37297052-1E91FD52-804E-4D3E-9610-EE65F56840C7Q37322650-F73082D6-F00F-4EA6-941F-DFB6ADC0BCA4Q37356071-238657DB-61E2-4E5F-AD68-0DF236A2145BQ37945171-5AEC453B-BC9D-4C49-8B3F-A1465A599449Q38199151-14BFEC54-F0EB-43AB-8048-CAB500120F7CQ38255634-A94E087B-E1D7-4556-8E94-0EE1D34D73B9Q38763575-2B39EA1A-F2BB-46D7-8949-628308772419Q38853141-A31B958C-D33D-4A39-A1AF-81BB6CC33EE0
P2860
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
An alphavirus replicon particl ...... based vaccine delivery vector.
@ast
An alphavirus replicon particl ...... based vaccine delivery vector.
@en
type
label
An alphavirus replicon particl ...... based vaccine delivery vector.
@ast
An alphavirus replicon particl ...... based vaccine delivery vector.
@en
prefLabel
An alphavirus replicon particl ...... based vaccine delivery vector.
@ast
An alphavirus replicon particl ...... based vaccine delivery vector.
@en
P2093
P2860
P1433
P1476
An alphavirus replicon particl ...... based vaccine delivery vector.
@en
P2093
Barbara Doe
Catherine E Greer
Gillis R Otten
Harold Legg
John M Polo
Kent Thudium
Michael Vajdy
Raul E Romero
P2860
P304
10394-10403
P356
10.1128/JVI.77.19.10394-10403.2003
P407
P577
2003-10-01T00:00:00Z